BioConnection congratulates BioLineRx with their FDA approval of Aphexda.
We are proud that we have been able to support BioLineRx since the start of the Motixafortide BL-8040 project (and even before) and be their proud partner through all the clinical phases. It is a tremendous and well-deserved success that Aphexda is now approved to the market. After our recent successful pre-approval FDA inspection we are ready to grow further with BioLineRx with the commercial supply. We congratulate the whole BiolineRX team with this success and hope that many patients will benefit from Aphexda!
You can read the original press release here.
